RxDoctor Payments DataLook up a doctor →

Jared Hossack, MD

Gastroenterology · Newark, DENPI 1316106636

Payments from drug & device makers

$9,471in general payments, 2019–2025

Across 524 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$856
  • Johnson & Johnson$749
  • Bristol Myers Squibb$430
  • Madrigal Pharmaceuticals$311
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$9,34699%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,471 in reported general payments places this provider in the 80th percentile of 50 gastroenterology providers in Delaware.

See all gastroenterology providers in Delaware

Medicare billing

Part B allowed, 2024
$211,244
Medicare patients
510
Services billed
5,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab18$541,743
LinzessLinaclotide44$44,125
Mesalamine23$21,305
Dexlansoprazole DrDexlansoprazole20$5,783
Pantoprazole Sodium164$4,832
Omeprazole264$3,537
Esomeprazole Magnesium51$2,210
Famotidine108$1,386
Dicyclomine Hcl57$1,338
Colestipol Hcl15$803
Ondansetron OdtOndansetron17$790
Lansoprazole20$659
Ondansetron Hcl15$452
ConstuloseLactulose13$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$749$541,74318 claims
AbbVieLinzess$3,313$44,12544 claims
SandozLansoprazole$17$65920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 gastroenterology providers in Delaware.

Other gastroenterology in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →